Medicine information TOFACITINIB STADA 10mg film-coated tablets

Product code:
W72325001
Indicated for:
autoimmune inflammatory diseases
Route of administration:
oral
Substance:
tofacitinib (JAK inhibitor)
ATC
L04AF01 — Antineoplastic and immunomodulating agents | Immunosuppressants | Immunosuppressants | Janus-associated kinase (JAK) inhibitors
Tofacitinib is a Janus kinase (JAK) inhibitor used in the treatment of rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. It works by inhibiting the JAK-STAT signaling pathway, reducing inflammation and the abnormal immune response associated with these conditions.

Tofacitinib is administered orally, usually twice daily, with the dose adjusted based on the patient's response and tolerability. It is often used as a second-line therapy for patients who do not respond adequately to conventional treatments.

Common side effects include upper respiratory tract infections, nausea, headache, and increased cholesterol levels. In rare cases, severe adverse reactions such as serious infections, thrombosis, or liver function impairment may occur. Regular monitoring of clinical parameters is essential during treatment.

Tofacitinib is an innovative therapeutic option for patients with chronic inflammatory diseases, contributing to symptom relief and improved quality of life.

General data about TOFACITINIB STADA 10mg

Substance:
tofacitinib
Product code:
W72325001
Strength:
10mg
Pharmaceutical form:
film-coated tablets
Product type:
Generic medicine
Prescription status:
S — Medicines dispensed with a restricted medical prescription, reserved for use in certain specialized fields.

Marketing authorisation

Manufacturer:
STADA ARZNEIMITTEL AG - GERMANIA
Holder:
STADA ARZNEIMITTEL AG - GERMANIA
Number:
16995/2026/01
Shelf life:
3 years

Pharmaceutical forms available for tofacitinib

Strengths available for tofacitinib

  • 10mg
  • 11mg
  • 1mg/ml
  • 5mg

Warnings:

Avoid grapefruit

Avoid grapefruit and grapefruit juice.

Avoid live vaccines

Avoid live vaccines during treatment if contraindicated.

Immunosuppression / infection risk

This medicine may increase the risk of infections.

Breastfeeding warning

Use during breastfeeding only on medical advice.

Pregnancy warning

Use during pregnancy only on medical advice.